Favirept®, an equine F(ab’)2-based antivenom, is a polyspecific product that covers the envenoming by most of the venomous snakes in the Middle East and North Africa.  These belong to the genera Bitis, Echis, Naja, Cerastes and Macrovipera.  Favirept® had a long history of safe and effective use until it was withdrawn in 2015.  MicroPharm is developing a new manufacturing process for the product with the aim of re-establishing supplies in 2026.